Jasper Therapeutics (JSPR) Stock Overview
A clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
JSPR Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Jasper Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.41 |
| 52 Week High | US$7.19 |
| 52 Week Low | US$0.34 |
| Beta | 3.01 |
| 1 Month Change | -50.30% |
| 3 Month Change | -52.98% |
| 1 Year Change | -92.58% |
| 3 Year Change | -97.04% |
| 5 Year Change | -99.59% |
| Change since IPO | -99.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| JSPR | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -17.8% | 7.5% | -2.5% |
| 1Y | -92.6% | 40.9% | 19.0% |
Return vs Industry: JSPR underperformed the US Biotechs industry which returned 40.9% over the past year.
Return vs Market: JSPR underperformed the US Market which returned 19% over the past year.
Price Volatility
| JSPR volatility | |
|---|---|
| JSPR Average Weekly Movement | 18.4% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: JSPR's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: JSPR's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 22 | Jeet Mahal | jaspertx.com |
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma.
Jasper Therapeutics, Inc. Fundamentals Summary
| JSPR fundamental statistics | |
|---|---|
| Market cap | US$9.55m |
| Earnings (TTM) | -US$55.73m |
| Revenue (TTM) | n/a |
Is JSPR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JSPR income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$55.73m |
| Earnings | -US$55.73m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.99 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did JSPR perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/29 22:27 |
| End of Day Share Price | 2026/06/29 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Jasper Therapeutics, Inc. is covered by 12 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Timothy Chiang | Capital One Securities, Inc. |
| Silvan Tuerkcan | Citizens JMP Securities, LLC |
| Gavin Clark-Gartner | Evercore ISI |